HER2 targeted therapies have dramatically improved the prognosis of HER2-positive breast cancer patients in the adjuvant and neoadjuvant settings and in metastatic disease [1], and of patients with HER2-positive metastatic gastric cancer [2]. This evidence concerns the gene ERBB2 and metastatic neoplasm.